Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Am J Trop Med Hyg ; 75(2): 267-9, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16896130

RESUMO

Mucosal leishmaniasis (ML) is often clinically silent until reaching a highly advanced state. In this prospective study, 6 of 220 patients with early cutaneous leishmaniasis were diagnosed with mucosal involvement by otorhinolaryngological examination (a rate similar to the reported rate of late ML). Detection of early ML may represent an important strategy in preventing severe mucosal destruction in human leishmaniasis.


Assuntos
Leishmaniose Cutânea/complicações , Leishmaniose Mucocutânea/complicações , Leishmaniose Mucocutânea/diagnóstico , Adolescente , Adulto , Idoso , Animais , Anticorpos Antiprotozoários/sangue , Brasil , Endoscopia/métodos , Feminino , Humanos , Leishmaniose Cutânea/diagnóstico , Masculino , Pessoa de Meia-Idade , Mucosa Nasal/parasitologia , Mucosa Nasal/patologia , Estudos Prospectivos , Testes Cutâneos/métodos
2.
Am J Trop Med Hyg ; 85(1): 70-3, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21734128

RESUMO

Cutaneous leishmaniasis (CL) is a worldwide disease endemic in several regions of the globe. The hallmark of CL is skin ulcers likely driven by efforts of the immune system to control Leishmania growth. Cytokines, such as tumor necrosis factor (TNF) and interferon-gamma can control disease progression in animal models. Nevertheless, the impact of these cytokines in CL ulcer outcome is not well established in humans. In this study, 96 CL patients from an endemic area of Leishmania braziliensis were enrolled for a follow-up study that consisted of clinical and immunological evaluations in a 2-year period. Statistical analysis revealed that healing time (P = 0.029), age (P = 0.002), and TNF levels (P = 0.0002) positively correlate with ulcer size at the time of the first clinical evaluation. Our findings suggest that ulcer size correlates with healing time and TNF levels support the use of TNF inhibitors combined with standard therapy to improve healing in CL patients with severe lesions.


Assuntos
Antígenos de Protozoários/imunologia , Leishmania/imunologia , Leishmaniose Cutânea/patologia , Fator de Necrose Tumoral alfa/metabolismo , Adolescente , Adulto , Idoso , Feminino , Humanos , Leishmaniose Cutânea/metabolismo , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa